EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Silence is not always Golden: Should we perform catheter ablation in asymptomatic atrial fibrillation? Clinical debate and emerging evidence

Marco Schiavone, Luigi Di Biase

Progress in Cardiovascular Diseases · 2025

DOI: 10.1016/j.pcad.2025.10.004 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Progress in Cardiovascular Diseases, 2025. Verfasst von Marco Schiavone und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Electrophysiology & Cardiac Pacing, Centro Cardiologico Monzino IRCCS, Milan, Italy. Hauptthemen laut MEDLINE: Atrial Fibrillation, Catheter Ablation, Heart Rate. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atrial fibrillation (AF) is a growing global health burden and a leading cause of morbidity and mortality. A significant proportion of AF episodes are asymptomatic or subclinical, leading to underdiagnosis and delayed treatment. Despite traditionally reserving rhythm control-particularly catheter ablation-for symptomatic patients, emerging evidence suggests that asymptomatic individuals face similar risks of stroke, heart failure, and AF progression. Recent data challenge the assumption that asymptomatic AF represents a benign phenotype. Meta-analyses and registry studies show comparable rates of adverse outcomes between symptomatic and asymptomatic patients and highlight AF progression as more frequent in the latter group, if left untreated. Randomized trials such as EAST-AFNET 4 and multiple ablation-first studies (e.g., EARLY-AF, Cryo-FIRST) support early rhythm control, with a growing rationale to consider it even in the absence of symptoms. Furthermore, pulsed field ablation (PFA) represents a transformative innovation, offering tissue-selective, non-thermal lesion creation with promising early clinical data. While routine ablation for all asymptomatic patients is not yet guideline-recommended, evolving evidence and improved safety profiles support a more proactive rhythm control strategy in selected individuals. Shared decision-making, grounded in risk stratification and patient-specific factors, is essential. As new data emerge, the case for expanding ablation indications to include asymptomatic AF continues to strengthen.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationCatheter AblationHeart RateHumansAsymptomatic DiseasesTreatment OutcomeRisk FactorsRisk AssessmentClinical Decision-MakingPatient Selection

Stichwörter der Autor:innen

Asymptomatic patientsAtrial fibrillationCatheter ablationPulsed field ablationRhythm control

Autor:innen und Institutionen

  • Department of Clinical Electrophysiology & Cardiac Pacing, Centro Cardiologico Monzino IRCCS, Milan, Italy.
  • Cardiac Arrhythmia Center, Division of Cardiology at Montefiore-Einstein Center, Bronx, NY, USA. Electronic address: dibbia@gmail.com.

Zitieren

APA

Schiavone, M., & Di Biase, L. (2025). Silence is not always Golden: Should we perform catheter ablation in asymptomatic atrial fibrillation? Clinical debate and emerging evidence. Progress in Cardiovascular Diseases. https://doi.org/10.1016/j.pcad.2025.10.004

Vancouver

Schiavone M, Di Biase L. Silence is not always Golden: Should we perform catheter ablation in asymptomatic atrial fibrillation? Clinical debate and emerging evidence. Progress in Cardiovascular Diseases. 2025. doi:10.1016/j.pcad.2025.10.004

BibTeX
@article{Schiavone2025,
  author = {Schiavone, Marco and Di Biase, Luigi},
  title = {Silence is not always Golden: Should we perform catheter ablation in asymptomatic atrial fibrillation? Clinical debate and emerging evidence},
  journal = {Progress in Cardiovascular Diseases},
  year = {2025},
  doi = {10.1016/j.pcad.2025.10.004}
}
Kostenlos starten →